Genexine Competitors and Similar CompaniesClear all
Genexine's competitors and similar companies include Travere Therapeutics, JCR Pharmaceuticals, GBT (Global Blood Therapeutics) and Kamada Pharmaceuticals.
 Genexine Genexine is a biotechnology company focused on the development and commercialization of immunotherapeutics and long-acting biologics. |  Travere Therapeutics Travere Therapeutics is a biopharmaceutical company that focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases. |  JCR Pharmaceuticals JCR Pharmaceuticals is a company that specializes in the development of pharmaceutical products. |  GBT (Global Blood Therapeutics) GBT (Global Blood Therapeutics) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. |  Kamada Pharmaceuticals Kamada Pharmaceuticals is a company that develops plasma-derived protein therapeutics for orphan indications. | |
Founding Date | Founding Date 1999 | Founding Date 2011 | Founding Date 1975 | Founding Date 2012 | Founding Date 1990 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Seongnam-si, KR HQ New York, US | Locations San Diego, US HQ Dublin, IE | Locations Ashiya, JP HQ Kobe, JP Kobe, JP Kobe, JP Kobe, JP | Locations South San Francisco, US HQ Paris, FR Berlin, DE Baar, CH London, GB | Locations Rehovot, IL HQ Beit Kama, IL |
Employees | Employees 8612% decrease | Employees 46293% increase | Employees 9346% increase | Employees 352106% increase | Employees 378 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 983.7 m | Valuation ($) 565.5 m | Valuation ($) 4.4 b | Valuation ($) 330.5 m |
Financial | |||||
Revenue (est.) | Revenue (est.) ₩16.1b (FY, 2022) | Revenue (est.) $145.2m (FY, 2023) | Revenue (est.) ¥42.9b (FY, 2024) | Revenue (est.) $194.7m (FY, 2021) | Revenue (est.) $142.5m (FY, 2023) |
Cost of goods | Cost of goods (₩2.1b) (FY, 2022) | Cost of goods $11.5m (FY, 2023) | Cost of goods ¥8.4b (FY, 2024) | Cost of goods $3.3m (FY, 2021) | Cost of goods $61.7m (FY, 2023) |
Gross profit | Gross profit ₩20.3b (FY, 2022) | Gross profit $133.8m (FY, 2023) | Gross profit ¥34.4b (FY, 2024) | Gross profit N/A | Gross profit $80.8m (FY, 2023) |
Net income | Net income (₩57.1b) (FY, 2022) | Net income ($111.4m) (FY, 2023) | Net income ¥5.5b (FY, 2024) | Net income ($303.1m) (FY, 2021) | Net income $8.3m (FY, 2023) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 25m | Total funding raised N/A | Total funding raised $ 88.7m | Total funding raised $ 90m |
For sources of this data, please see the company profile
View Company Profiles
Travere Therapeutics
HQ
San Diego, US
Employees
462
Travere Therapeutics is a biopharmaceutical company that focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases.
View companyJCR Pharmaceuticals
HQ
Ashiya, JP
Employees
934↑ 6% increase
JCR Pharmaceuticals is a company that specializes in the development of pharmaceutical products.
View companyGBT (Global Blood Therapeutics)
HQ
South San Francisco, US
Employees
352
GBT (Global Blood Therapeutics) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need.
View companyKamada Pharmaceuticals
HQ
Rehovot, IL
Employees
378
Kamada Pharmaceuticals is a company that develops plasma-derived protein therapeutics for orphan indications.
View company